# Metformin to Reduce Airway Glucose in COPD Patients

> **NCT03651895** · PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 14 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03651895
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-17
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-06-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03651895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03651895, "Metformin to Reduce Airway Glucose in COPD Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03651895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*